Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance
INDIANAPOLIS, Jan. 29, 2013 /PRNewswire/ --
Fourth quarter revenue declined 1 percent driven by Zyprexa
patent expiration, largely offset by growth in other
products.
Fourth quarter earnings per share were $0.74 (reported), or $0.85...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Zyprexa